Dasabuvir (CAT: I000498) is an antiviral medication used in combination therapy for the treatment of chronic hepatitis C virus (HCV) infection. It belongs to the class of drugs known as NS5B polymerase inhibitors. Dasabuvir specifically targets the HCV nonstructural protein 5B (NS5B) polymerase, which is essential for viral replication. By inhibiting NS5B polymerase, dasabuvir disrupts the replication process of HCV, ultimately reducing the viral load in the body. It is typically used in combination with other antiviral agents as part of a comprehensive treatment regimen for chronic HCV infection.
| Catalog Number | I000498 |
| CAS Number | 1132935-63-7 |
| Synonyms | ABT333; ABT-333; ABT 333 |
| Molecular Formula | C26H27N3O5S |
| Purity | 95% |
| Target | HCV |
| Solubility | DMSO: ≥ 46 mg/mL |
| Storage | Store at -20°C |
| InChI | InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31) |
| InChIKey | NBRBXGKOEOGLOI-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C1=C(OC)C(C2=CC3=CC=C(NS(C)(=O)=O)C=C3C=C2)=CC(N4C=CC(NC4=O)=O)=C1 |
| Reference | 1: King JR, Zha J, Khatri A, Dutta S, Menon RM. Clinical Pharmacokinetics of 2: Mantry PS, Pathak L. Dasabuvir (ABT333) for the treatment of chronic HCV <br> <br> <br> |
